A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration

ConditionDry Age Related Macular Degeneration

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age50+

SponsorEyevensys

About this trial

The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).

The main question it aims to answer is: Is PST-611-CT1 safe for participants?

Participants will:

* Receive a single dose of PST-611 * Will be followed up for a total of 16 weeks following PST-611 administration

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

PST-611

Treatment groups

12 Participants

are divided into 1 treatment group

Sponsors and collaborators

Eyevensys

Lead sponsor

Source ClinicalTrials.gov